Dipexium Pharmaceuticals Inc. (Nasdaq: DPRX) reported disappointing results from a Phase 3 trial of its mild diabetic foot infection treatment Locilex sending the stock price plummeting $9.95 to close at $2.80.
Dipexium Pharmaceuticals reports disappointing results
October 25, 2016 at 20:27 PM EDT
